StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Free Report) in a research report released on Saturday morning. The brokerage issued a sell rating on the basic materials company’s stock.
Several other analysts also recently commented on the stock. HC Wainwright lowered their target price on shares of Arcadia Biosciences from $10.00 to $6.00 and set a buy rating for the company in a report on Thursday, May 23rd. Lake Street Capital upgraded shares of Arcadia Biosciences to a strong-buy rating in a report on Tuesday, May 14th.
Read Our Latest Analysis on Arcadia Biosciences
Arcadia Biosciences Price Performance
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last announced its earnings results on Thursday, May 9th. The basic materials company reported ($1.78) EPS for the quarter, beating the consensus estimate of ($2.52) by $0.74. The company had revenue of $1.26 million during the quarter, compared to the consensus estimate of $1.20 million. Arcadia Biosciences had a negative net margin of 129.74% and a negative return on equity of 84.27%. During the same quarter in the prior year, the company posted ($3.83) earnings per share. As a group, research analysts expect that Arcadia Biosciences will post -2.29 earnings per share for the current fiscal year.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
See Also
- Five stocks we like better than Arcadia Biosciences
- Stock Dividend Cuts Happen Are You Ready?
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Dividend Payout Ratio Calculator
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- The How And Why of Investing in Oil Stocks
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.